3 Drugs Stocks Moving The Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 90 points (0.6%) at 15,153 as of Tuesday, Sept. 10, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,842 issues advancing vs. 1,092 declining with 95 unchanged.

The Drugs industry currently sits up 0.3% versus the S&P 500, which is up 0.5%. A company within the industry that increased today was Sanofi ( SNY), up 1.3%. On the negative front, top decliners within the industry include Vertex Pharmaceuticals ( VRTX), down 2.4%, and Biomarin Pharmaceutical ( BMRN), down 2.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Novo Nordisk A/S ( NVO) is one of the companies pushing the Drugs industry higher today. As of noon trading, Novo Nordisk A/S is up $2.25 (1.4%) to $166.39 on light volume. Thus far, 101,956 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 323,200 shares. The stock has ranged in price between $165.26-$166.50 after having opened the day at $165.43 as compared to the previous trading day's close of $164.14.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $88.9 billion and is part of the health care sector. Shares are down 0.9% year to date as of the close of trading on Monday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Novo Nordisk A/S Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Merck ( MRK) is up $0.30 (0.6%) to $48.04 on average volume. Thus far, 5.7 million shares of Merck exchanged hands as compared to its average daily volume of 12.9 million shares. The stock has ranged in price between $47.86-$48.40 after having opened the day at $47.95 as compared to the previous trading day's close of $47.74.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $139.0 billion and is part of the health care sector. Shares are up 16.0% year to date as of the close of trading on Monday. Currently there are 8 analysts that rate Merck a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Johnson & Johnson ( JNJ) is up $0.63 (0.7%) to $88.19 on light volume. Thus far, 3.5 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9.5 million shares. The stock has ranged in price between $87.85-$88.26 after having opened the day at $88.14 as compared to the previous trading day's close of $87.56.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $245.6 billion and is part of the health care sector. Shares are up 24.3% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

'Strong Case for More Rate Hikes,' Says Fed Chair Jerome Powell

'Strong Case for More Rate Hikes,' Says Fed Chair Jerome Powell

A Thunderous Herd of Scared Baby Boomer Investors Could Crush the Market

A Thunderous Herd of Scared Baby Boomer Investors Could Crush the Market

Disney Tops Comcast Bid With Improved $71.3 Billion Approach for Fox

Disney Tops Comcast Bid With Improved $71.3 Billion Approach for Fox

With GE Dropped From the Dow, Be Selective About Industrials Stocks

With GE Dropped From the Dow, Be Selective About Industrials Stocks

MoviePass Parent's Stock Plunges as AMC Announces Rival Program

MoviePass Parent's Stock Plunges as AMC Announces Rival Program